IDEAS home Printed from https://ideas.repec.org/a/bla/ajecsc/v81y2022i4p721-751.html

When Will the FDA Do What Is in People’s Best Interests?

Author

Listed:
  • Alfred B. Ordman

Abstract

The national effort to reduce the incidence and severity of cancer and other chronic diseases in the United States has suffered from political influences that undermine the interests of the public. As one example, the medical profession has not made adequate use of nutritional information to improve the health of the population. Daily values for vitamins were established in the United States during World War II, when the goal was to avoid short‐term deficiencies so soldiers could continue to fight. But there is more to health than short‐term survival. Linus Pauling advocated megadoses of vitamin C to reduce the risk of cancer and to improve long‐term health. Despite numerous studies demonstrating that better nutrition and exercise are vital to a longer span of good health, the U.S. Food and Drug Administration (FDA) does not permit claims to be made about the health benefits of specific nutritional supplements. The FDA is responsive to political pressures, including pressures to reduce public knowledge of supplements and their benefits. Pharmaceutical companies contribute to members of Congress to influence health policy. Those companies promote legislation and regulations that favor the use of expensive medical treatments and that limit the provision of cost‐effective public health measures. This article reviews many examples of failures of our current medical system, and methods that could prevent the current expense and suffering in this nation.

Suggested Citation

  • Alfred B. Ordman, 2022. "When Will the FDA Do What Is in People’s Best Interests?," American Journal of Economics and Sociology, Wiley Blackwell, vol. 81(4), pages 721-751, September.
  • Handle: RePEc:bla:ajecsc:v:81:y:2022:i:4:p:721-751
    DOI: 10.1111/ajes.12481
    as

    Download full text from publisher

    File URL: https://doi.org/10.1111/ajes.12481
    Download Restriction: no

    File URL: https://libkey.io/10.1111/ajes.12481?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. DiMasi, Joseph A. & Grabowski, Henry G. & Hansen, Ronald W., 2016. "Innovation in the pharmaceutical industry: New estimates of R&D costs," Journal of Health Economics, Elsevier, vol. 47(C), pages 20-33.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Javad Moradpour & Aidan Hollis, 2020. "Patient income and health innovation," Health Economics, John Wiley & Sons, Ltd., vol. 29(12), pages 1795-1803, December.
    2. Gemma Turon & Jason Hlozek & John G. Woodland & Ankur Kumar & Kelly Chibale & Miquel Duran-Frigola, 2023. "First fully-automated AI/ML virtual screening cascade implemented at a drug discovery centre in Africa," Nature Communications, Nature, vol. 14(1), pages 1-11, December.
    3. Du, Weijian & Li, Mengjie & Wang, Faming, 2020. "Role of rent-seeking or technological progress in maintaining the monopoly power of energy enterprises: An empirical analysis based on micro-data from China," Energy, Elsevier, vol. 202(C).
    4. Ian Goldin & Pantelis Koutroumpis & François Lafond & Julian Winkler, 2024. "Why Is Productivity Slowing Down?," Journal of Economic Literature, American Economic Association, vol. 62(1), pages 196-268, March.
    5. Tamar Oostrom, 2024. "Funding of Clinical Trials and Reported Drug Efficacy," Journal of Political Economy, University of Chicago Press, vol. 132(10), pages 3298-3333.
    6. Manuel Hermosilla, 2021. "Rushed Innovation: Evidence from Drug Licensing," Management Science, INFORMS, vol. 67(1), pages 257-278, January.
    7. Nagesh N. Murthy & Haikady N. Nagaraja & Hossein Rikhtehgar Berenji, 2023. "Managing concurrency in cyclical projects under stochastic task environments: Vaccine development projects during pandemics," Production and Operations Management, Production and Operations Management Society, vol. 32(3), pages 951-971, March.
    8. Arpine Martirosyan & Jae Wook Yoo, 2025. "The Effect of Ownership Concentration on the Catch-Up Speed of the Second Mover: Evidence From the Pharmaceutical Industry of South Korea," SAGE Open, , vol. 15(2), pages 21582440251, May.
    9. Ricardo Arcaro & Cássia Rita Pereira da Veiga & Wesley Vieira da Silva & Claudimar Pereira da Veiga, 2021. "Attitude and Purchase Intention to Generic Drugs," IJERPH, MDPI, vol. 18(9), pages 1-16, April.
    10. Sanzenbacher, Geoffrey T. & Wettstein, Gal, 2020. "Drug insurance and the strategic behavior of drug manufacturers: Evergreening and generic entry after Medicare Part D," Journal of Health Economics, Elsevier, vol. 72(C).
    11. Adrian Towse;Jimena Ferraro;Jorge Mestre-Ferrandiz, 2017. "Incentives for New Drugs to Tackle Anti-Microbial Resistance," Briefing 001842, Office of Health Economics.
    12. Stig Johan Wiklund, 2019. "A modelling framework for improved design and decision-making in drug development," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-22, August.
    13. Jacopo Umberto Verga & Matthew Huff & Diarmuid Owens & Bethany J. Wolf & Gary Hardiman, 2022. "Integrated Genomic and Bioinformatics Approaches to Identify Molecular Links between Endocrine Disruptors and Adverse Outcomes," IJERPH, MDPI, vol. 19(1), pages 1-24, January.
    14. Amrita Lahiri & Chandresh Baid & Arvin Sahaym & Greg Fisher, 2025. "When Failure Is Not Fatal: Examining Venture Resource Acquisition Following Product Development Failure," Entrepreneurship Theory and Practice, , vol. 49(1), pages 196-231, January.
    15. Angelo Kenneth S. Romasanta & Peter Sijde & Jacqueline Muijlwijk-Koezen, 2020. "Innovation in pharmaceutical R&D: mapping the research landscape," Scientometrics, Springer;Akadémiai Kiadó, vol. 125(3), pages 1801-1832, December.
    16. Crego, Julio & Kárpáti, Daniel & Kværner, Jens & Renneboog, Luc, 2022. "The Economic Value of Eliminating Diseases," Discussion Paper 2022-029, Tilburg University, Center for Economic Research.
    17. Steffen Nauhaus & Johannes Luger & Sebastian Raisch, 2021. "Strategic Decision Making in the Digital Age: Expert Sentiment and Corporate Capital Allocation," Journal of Management Studies, Wiley Blackwell, vol. 58(7), pages 1933-1961, November.
    18. Farasat A. S. Bokhari & Franco Mariuzzo & Anna Rita Bennato, 2021. "Innovation and growth in the UK pharmaceuticals: the case of product and marketing introductions," Small Business Economics, Springer, vol. 57(1), pages 603-634, June.
    19. Viswanath Pingali & Neelima Das, 2021. "Rare Diseases Require Support Too," Vikalpa: The Journal for Decision Makers, , vol. 46(2), pages 129-134, June.
    20. Dosis, Anastasios & Muthoo, Abhinay, 2019. "Experimentation in Dynamic R&D Competition," CRETA Online Discussion Paper Series 52, Centre for Research in Economic Theory and its Applications CRETA.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bla:ajecsc:v:81:y:2022:i:4:p:721-751. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www.blackwellpublishing.com/journal.asp?ref=0002-9246 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.